Kannaway Enters European CBG Market

Kannaway, a subsidiary of Medical Marijuana, Inc., the first publicly traded cannabis company in the U.S., launched Kannaway Premium CBG with Organic Hemp Seed Oil into the European cannabigerol (CBG) market.

“Since launching in Europe in 2018, Europe has become one of our best revenue-generating markets as consumers have responded very positively to Kannaway’s wide range of cannabidiol (CBD) products,” says Medical Marijuana, Inc. Chief Executive Officer Dr. Stuart Titus. “Similar to CBD, CBG is non-psychoactive, meaning it does not cause intoxicating effects. Researchers have conducted and are currently conducting many interesting studies on CBG. We are excited to broaden our product offerings with CBG and are confident the market will be as well.”

Kannaway Premium CBG with Organic Hemp Seed Oil contains 500 mg of CBG and 200 mg of CBD in each bottle that are derived from organic European hemp.

“As CBD continues to grow in acceptance around the world, the market for cannabinoids like CBG also expands,” says Kannaway Chief Executive Officer Blake Schroeder. “Our company intends to continue to be at the forefront of expanding access to cannabinoids just as we have been with CBD.”